The FDA has cleared Wright Medical Group’s Pro-Stim Injectable Osteoinductive Bone Graft Substitute, allowing a limited group of trial centers to validate pre-clinical findings in clinical use, according to a release from Wright Medical Group.
The Pro-Stim graft provides surgeons with the osteoconductive base material derived from its Pro-Dense graft, which is a combination of calcium sulfate and calcium phosphate materials, but adds a high volume of osteoinductive demineralized bone matrix to the formulation.
A full roll-out in the United States and some international markets is planned for the second half of 2010.
Read Wright Medical Group’s release on the Pro-Stim bone graft substitute.
From findings on cervical disc replacement to total knee replacement, Becker’s reported on eight spine and orthopedic studies since March…
Researchers at UMass Chan Medical School in Worcester, Mass., have created an algorithm to predict total knee replacement outcomes in…
Orthopaedic Solutions Management has acquired Orlando Hand Surgical Associates, marking its eighth acquisition. OHSA was founded in 2000 and has…
Comments are closed.